CMMB stock news · Chemomab Therapeutics
Get alerts for CMMB
Follow Chemomab Therapeutics (CMMB) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for CMMBFree on the App Store and Google Play, or on the web.
Chemomab Therapeutics reported a loss last quarter and shared news about its merger and FDA trial plans.
NeutralChemomab reported a $5.1 million third-quarter loss, up from $1.7 million a year earlier, and shared updates on its proposed Scipher merger and FDA talks. The mixed news does not clearly change its outlook.
12 health care companies are seeing big changes in their stock prices today.
NeutralChemomab Therapeutics shares fell 23% to $1.24. The article gives no company news explaining the move, so it does not change the business outlook.